Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Third Quarter Earnings

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2012 Third Quarter financial results before the U.S. stock market opens on Tuesday, January 17, 2012. At 10:00 AM EDT, Forest will host a conference call where Elaine Hochberg, Executive Vice President and Chief Commercial Officer, Frank Perier, Executive Vice President Finance & Administration and Chief Financial Officer, and Dr. Marco Taglietti, Senior Vice President Research & Development and President, Forest Research Institute, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website www.frx.com and also on the website www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until February 1, 2012 at both websites and also by dialing 1-800-585-8367 (US and Canada) or +1-855-859-2056 (international), Conference Call ID # 37551625.

About Forest Laboratories

Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine. The Company’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.